Exchange
Nasdaq
Every company in the roster listed on Nasdaq.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
280 of 280 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Can-Fite BioPharmaCANF · Nasdaq | 2 assets: 2 Ph 3 | NamodenosonPhase 3 · Hepatocellular CarcinomaPartial signal | 31 Aug 2027Piclidenoson · Phase 2 |
 Celldex TherapeuticsCLDX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | barzolvolimabPhase 3 · Chronic Spontaneous Urticaria | Mar 2027CDX-622 · Phase 1 |
 Compass TherapeuticsCMPX · Nasdaq | 2 assets: 1 Ph 1, 1 other | CTX-8371Phase 1 · Non-Small Cell Lung Cancer | Dec 2026CTX-8371 · Phase 1 |
 Corbus PharmaceuticalsCRBP · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | CRB-701Phase 3 · Cervical Cancer | 16 Jan 2027CRB-701 · Phase 1/2 |
 Cumberland Pharmaceuticals Inc.CPIX · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | IfetrobanPhase 2 · Systemic Sclerosis | Jan 2028Ifetroban · Phase 2 |
 Enanta Pharmaceuticals, Inc.ENTA · Nasdaq | 2 assets: 2 Ph 2 | EDP-323Phase 2 · Respiratory Syncytial Virus InfectionPartial signal | Dec 2026zelicapavir · Phase 2 |
 ErascaERAS · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | NaporafenibPhase 3 · MelanomaWeak signal | 5 Oct 2026Naporafenib · Phase 1 |
 GH ResearchGHRS · Nasdaq | 2 assets: 2 Ph 2 | Mebufotenin (5-MeO-DMT)Phase 2 · Major Depressive DisorderPartial signal | None on record |
 Galectin Therapeutics Inc.GALT · Nasdaq | 2 assets: 2 Ph 3 | belapectinPhase 2/3 · MASH / NASHPartial signal | None on record |
| 2 assets: 1 Ph 3, 1 Ph 2 | UproleselanPhase 3 · Relapsed/Refractory Acute Myeloid Leukemia | Feb 2029CR-001 · Phase 1/2 | |
 HUTCHMEDHCM · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | SavolitinibPhase 3 · Non-Small Cell Lung CancerPartial signal | 18 Jan 2027Savolitinib · Phase 2 |
 Harmony BiosciencesHRMY · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | Clemizole (EPX-100)Phase 3 · Epilepsy | 1 Nov 2026Clemizole (EPX-100) · Phase 3 |
 Immunic, Inc.IMUX · Nasdaq | 2 assets: 1 Ph 3, 1 other | vidofludimus calciumPhase 3 · Multiple Sclerosis | Nov 2026vidofludimus calcium · Phase 3 |
 ImmunityBioIBRX · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | HankPhase 2 · Non-Small Cell Lung Cancer | Nov 2026N-803 · Phase 2 |
 Immunocore Holdings plcIMCR · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | brenetafuspPhase 3 · Cutaneous Melanoma | 16 Oct 2027brenetafusp · Phase 3 |
 Inhibikase TherapeuticsIKT · Nasdaq | 2 assets: 2 Ph 2 | Risvodetinib (IkT-148009)Phase 2 · Parkinson's DiseasePartial signal | None on record |
 Ironwood PharmaceuticalsIRWD · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | apraglutidePhase 3 · Short Bowel Syndrome | None on record |
 Jade Biosciences, Inc.JBIO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | JADE101Phase 2 · IgA Nephropathy | May 2027JADE101 · Phase 1 |
 Janux TherapeuticsJANX · Nasdaq | 2 assets: 2 Ph 1 | JANX007Phase 1 · Prostate Cancer | Jul 2027JANX007 · Phase 1 |
 Kailera TherapeuticsKLRA · Nasdaq | 2 assets: 2 Ph 3 | HRS-7535Phase 3 · ObesityReliable signal | Dec 2026HRS-7535 · Phase 2 |
 KardiganKARD · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | DanicamtivPhase 3 · Heart FailurePartial signal | Dec 2026Tonlamarsen · Phase 2 |
 Karyopharm TherapeuticsKPTI · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | EltanexorPhase 1/2 · Multiple MyelomaWeak signal | Dec 2026Selinexor · Phase 2/3 |
 Kymera TherapeuticsKYMR · Nasdaq | 2 assets: 2 Ph 2 | KT-474Phase 2 · Hidradenitis Suppurativa | Jun 2027KT-621 · Phase 2 |
 Kyntra BioKYNB · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal | 30 Oct 2027Roxadustat · Phase 3 |
 Lakefront Biotherapeutics NVLKFT · Nasdaq | 2 assets: 2 Ph 2 | GLPG3667Phase 2 · Dermatomyositis | None on record |
 Legend Biotech CorporationLEGN · Nasdaq | 2 assets: 1 approved, 1 other | LCAR-F33SMultiple Myeloma | 26 Feb 2027Ciltacabtagene autoleucel · Phase 2 |
 Lexaria BioscienceLEXX · Nasdaq | 2 assets: 2 Ph 1 | DehydraTECH-CBD/semaglutidePhase 1 · ObesityPartial signal | None on record |
 Lexicon PharmaceuticalsLXRX · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | PilavapadinPhase 2 · Diabetic Peripheral Neuropathic PainPartial signal | Jan 2027Sotagliflozin (Inpefa) · Phase 3 |
 Liquidia CorporationLQDA · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | L606Phase 3 · Hypertension | Feb 2027Treprostinil (Yutrepia, Liquidia) · Phase 2 |
 Lyell Immunopharma, Inc.LYEL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | Rondecabtagene autoleucelPhase 3 · Large B-Cell Lymphoma | Jun 2028LYL273 · Phase 1/2 |
 MediciNova, Inc.MNOV · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | AV411Phase 3 · Amyotrophic Lateral Sclerosis | 31 Dec 2026MN-001 · Phase 2 |
 Mereo BioPharmaMREO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | setrusumabPhase 3 · Osteogenesis Imperfecta | None on record |
 MetaViaMTVA · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | DA-1241Phase 2 · Type 2 DiabetesPartial signal | 9 Nov 2026DA-1726 · Phase 1 |
 Mirum Pharmaceuticals, Inc.MIRM · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | volixibatPhase 2 · Primary Sclerosing Cholangitis | Jan 2027volixibat · Phase 2 |
 Nektar TherapeuticsNKTR · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | rezpegaldesleukinPhase 3 · Atopic DermatitisPartial signal | May 2028rezpegaldesleukin · Phase 3 |
 Neonc Technologies, Inc.NTHI · Nasdaq | 2 assets: 1 Ph 2, 1 other | NEO212Phase 1/2 · Non-Small Cell Lung Cancer | 28 Feb 2027NEO212 · Phase 1/2 |
 Neumora Therapeutics, Inc.NMRA · Nasdaq | 2 assets: 1 Ph 1, 1 other | NMRA-323511Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 NovaBridge BiosciencesNBP · Nasdaq | 2 assets: 2 Ph 2 | olamkiceptPhase 2 · Ulcerative ColitisPartial signal | Dec 2026givastomig · Phase 1 |
 Omeros CorporationOMER · Nasdaq | 2 assets: 1 Ph 2, 1 other | zaltenibartPhase 2 · Paroxysmal Nocturnal Hemoglobinuria | None on record |
 Oruka TherapeuticsORKA · Nasdaq | 2 assets: 2 Ph 2 | ORKA-001Phase 2 · Psoriasis | Jan 2027ORKA-002 · Phase 1 |
 Prelude TherapeuticsPRLD · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | PRT3789Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record |
 Processa Pharmaceuticals, Inc.PCSA · Nasdaq | 2 assets: 1 Ph 2, 1 other | PCS6422Phase 2 · Metastatic Colorectal Cancer | None on record |
 Protagonist TherapeuticsPTGX · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | rusfertidePhase 3 · Polycythemia Vera | 10 Feb 2027icotrokinra · Phase 3 |
 Puma BiotechnologyPBYI · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | AlisertibPhase 3 · Small Cell Lung Cancer | 30 Oct 2027Alisertib · Phase 2 |
 RANI TherapeuticsRANI · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | PG-102Phase 2 · ObesityPartial signal | 1 Dec 2026PG-102 · Phase 1 |
 Recursion PharmaceuticalsRXRX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | REC-2282Phase 2/3 · Meningioma | None on record |
 Relay Therapeutics, Inc.RLAY · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | ZovegalisibPhase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Apr 2027Zovegalisib · Phase 1 |
 Seres TherapeuticsMCRB · Nasdaq | 2 assets: 1 approved, 1 other | SER-155Bacterial Infections in Allogeneic Stem Cell Transplant | None on record |
 TScan Therapeutics, Inc.TCRX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | TSC-101Phase 3 · Hematologic Malignancies | Jun 2029TSC-101 · Phase 3 |
 Veru Inc.VERU · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | enobosarmPhase 3 · ObesityPartial signal | Oct 2027enobosarm · Phase 2 |
 Voyager TherapeuticsVYGR · Nasdaq | 2 assets: 1 Ph 2, 1 other | VY7523Phase 1/2 · Alzheimer's Disease | May 2027VY7523 · Phase 1/2 |
 XBiotechXBIT · Nasdaq | 2 assets: 1 Ph 2, 1 other | NatrunixPhase 2 · Rheumatoid ArthritisPartial signal | 15 Jan 2027Natrunix · Phase 2 |
 ABVC BioPharmaABVC · Nasdaq | 1 asset: 1 Ph 2 | PDC-1421Phase 2 · Major Depressive DisorderPartial signal | 28 Feb 2028PDC-1421 · Phase 1/2 |
 AGIOS PHARMACEUTICALS, INC.AGIO · Nasdaq | 1 asset: 1 approved | Approved assets only | Mar 2029Mitapivat · Phase 3 |
 ARS Pharmaceuticals, Inc.SPRY · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 ATOSSA THERAPEUTICS, INC.ATOS · Nasdaq | 1 asset: 1 Ph 2 | (Z)-endoxifenPhase 2 · HR+/HER2- Metastatic Breast CancerPartial signal | Nov 2026(Z)-endoxifen · Phase 2 |
 AbivaxABVX · Nasdaq | 1 asset: 1 Ph 3 | obefazimodPhase 3 · Ulcerative ColitisReliable signal | Dec 2026obefazimod · Phase 2 |
 Aclaris TherapeuticsACRS · Nasdaq | 1 asset: 1 other | ATI-052Atopic Dermatitis | None on record |
 Acumen PharmaceuticalsABOS · Nasdaq | 1 asset: 1 Ph 2 | SabirnetugPhase 2 · Alzheimer's DiseasePartial signal | None on record |
 Agomab Therapeutics NVAGMB · Nasdaq | 1 asset: 1 Ph 2 | ontunisertibPhase 2 · Fibrostenosing Crohn's Disease | None on record |
 Ainos, Inc.AIMD · Nasdaq | 1 asset: 1 other | Interferon alfa (Veldona)Oral Warts in HIV Patients | None on record |
 Alaunos Therapeutics, Inc.TCRT · Nasdaq | 1 asset: 1 Ph 2 | DarinaparsinPhase 2 · Peripheral T-Cell Lymphoma | None on record |
 Aldeyra TherapeuticsALDX · Nasdaq | 1 asset: 1 Ph 3 | reproxalapPhase 3 · Dry Eye Disease | None on record |
 Aligos TherapeuticsALGS · Nasdaq | 1 asset: 1 Ph 2 | ALG-055009Phase 2 · Metabolic Dysfunction-Associated Steatohepatitis | None on record |
 Allarity Therapeutics, Inc.ALLR · Nasdaq | 1 asset: 1 Ph 2 | stenoparibPhase 2 · Ovarian Cancer | Mar 2027stenoparib · Phase 2 |
 Alpha Cognition Inc.ACOG · Nasdaq | 1 asset: 1 approved | Approved assets only | Apr 2027Benzgalantamine · Approved |
 AltimmuneALT · Nasdaq | 1 asset: 1 Ph 3 | pemvidutidePhase 3 · MASH / NASHPartial signal | 30 Sep 2027pemvidutide · Phase 2 |
 Alzamend NeuroALZN · Nasdaq | 1 asset: 1 Ph 2 | AL001Phase 1/2 · Alzheimer's Disease | Dec 2026AL001 · Phase 1/2 |
 Amarin CorporationAMRN · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 Amylyx Pharmaceuticals, Inc.AMLX · Nasdaq | 1 asset: 1 Ph 3 | avexitidePhase 3 · Post-Bariatric Hypoglycemia | None on record |
 AnaptysBioANAB · Nasdaq | 1 asset: 1 Ph 2 | RosnilimabPhase 2 · Rheumatoid Arthritis | None on record |
 Arbutus BiopharmaABUS · Nasdaq | 1 asset: 1 Ph 2 | AB-101Phase 1/2 · Systemic Lupus Erythematosus | None on record |
 Arcutis BiotherapeuticsARQT · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 ArdelyxARDX · Nasdaq | 1 asset: 1 approved | Approved assets only | 26 Feb 2027Tenapanor · Phase 3 |
 Assembly BiosciencesASMB · Nasdaq | 1 asset: 1 Ph 1 | ABI-5366Phase 1 · Genital Herpes | None on record |
 Autolus Therapeutics plcAUTL · Nasdaq | 1 asset: 1 approved | Approved assets only | Sep 2027obecabtagene autoleucel · Phase 1 |
 Avalyn Pharma Inc.AVLN · Nasdaq | 1 asset: 1 Ph 2 | AP01Phase 2 · Rheumatoid Arthritis | Jun 2027AP01 · Phase 2 |
 BeyondSpring PharmaceuticalsBYSI · Nasdaq | 1 asset: 1 Ph 3 | PlinabulinPhase 3 · Non-Small Cell Lung CancerPartial signal | 1 Jun 2029Plinabulin · Phase 3 |
 BioCardiaBCDA · Nasdaq | 1 asset: 1 Ph 3 | CardiAMPPhase 3 · Heart FailurePartial signal | 1 Apr 2027CardiAMP · Phase na |
 BioLineRx Ltd.BLRX · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 BioVie Inc. (NASDAQ: BIVI)BIVI · Nasdaq | 1 asset: 1 Ph 3 | BezisterimPhase 3 · Alzheimer's DiseasePartial signal | None on record |
 Bright Minds Biosciences Inc.DRUG · Nasdaq | 1 asset: 1 Ph 2 | BMB-101Phase 2 · Epilepsy | Nov 2026BMB-101 · Phase 2 |
 C4 Therapeutics, Inc.CCCC · Nasdaq | 1 asset: 1 Ph 2 | CemsidomidePhase 2 · Multiple Myeloma | Dec 2028Cemsidomide · Phase 1 |
 COMPASS PathwaysCMPS · Nasdaq | 1 asset: 1 Ph 3 | Psilocybin (COMP360)Phase 3 · Major Depressive DisorderReliable signal | Nov 2028Psilocybin (COMP360) · Phase 2/3 |
 Candel Therapeutics, Inc.CADL · Nasdaq | 1 asset: 1 Ph 3 | Aglatimagene BesadenovecPhase 3 · Non-Small Cell Lung Cancer | Feb 2027Aglatimagene Besadenovec · Phase 2 |
 Capricor TherapeuticsCAPR · Nasdaq | 1 asset: 1 Ph 3 | deramiocelPhase 3 · Duchenne Muscular Dystrophy | None on record |
 Cartesian Therapeutics, Inc.RNAC · Nasdaq | 1 asset: 1 Ph 3 | Descartes-08Phase 3 · Myasthenia Gravis | 1 Dec 2026Descartes-08 · Phase 2 |
 Celcuity Inc.CELC · Nasdaq | 1 asset: 1 approved | Approved assets only | Jan 2028Gedatolisib · Phase 1/2 |
 Cellectar Biosciences, Inc.CLRB · Nasdaq | 1 asset: 1 Ph 3 | Iopofosine I-131Phase 3 · Waldenstrom's MacroglobulinemiaWeak signal | 30 Jun 2027Iopofosine I-131 · Phase 1 |
 Celularity Inc.CELU · Nasdaq | 1 asset: 1 Ph 2 | CYNK-001Phase 1/2 · Acute Myeloid Leukemia | None on record |
 CervoMed Inc.CRVO · Nasdaq | 1 asset: 1 Ph 2 | neflamapimodPhase 2 · Dementia with Lewy Bodies | None on record |
 Clene NanomedicineCLNN · Nasdaq | 1 asset: 1 Ph 3 | CNM-Au8Phase 2/3 · Amyotrophic Lateral SclerosisPartial signal | None on record |
 Climb Bio, Inc.CLYM · Nasdaq | 1 asset: 1 Ph 2 | budoprutugPhase 1/2 · Systemic Lupus Erythematosus | Apr 2027budoprutug · Phase 1 |
 Cognition TherapeuticsCGTX · Nasdaq | 1 asset: 1 Ph 2 | ZervimesinePhase 2 · Alzheimer's DiseasePartial signal | 31 May 2027Zervimesine · Phase 2 |
 Coherus BioSciences, Inc.CHRS · Nasdaq | 1 asset: 1 approved | Approved assets only | 15 Dec 2026Toripalimab · Phase 1 |
 Connect BiopharmaCNTB · Nasdaq | 1 asset: 1 Ph 3 | RademikibartPhase 3 · Atopic DermatitisPartial signal | None on record |
 CorMedixCRMD · Nasdaq | 1 asset: 1 approved | Approved assets only | Jan 2028Taurolidine/heparin · Phase 3 |
 CybinHELP · Nasdaq | 1 asset: 1 Ph 3 | CYB003Phase 3 · Major Depressive DisorderPartial signal | 7 Jun 2027CYB003 · Phase 3 |
 Definium TherapeuticsDFTX · Nasdaq | 1 asset: 1 Ph 3 | Lysergide tartrate (LSD)Phase 3 · Major Depressive DisorderPartial signal | Sep 2027Lysergide tartrate (LSD) · Phase 3 |
 DiaMedica TherapeuticsDMAC · Nasdaq | 1 asset: 1 Ph 3 | DM199Phase 2/3 · Acute Ischemic Stroke | Dec 2026DM199 · Phase 2/3 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).